APFID

Home > Latest News on ID > Interesting Papers

LOGIN
Health economics of use fluoroquinolones to treat patients with CAP
Am J Med. 2010 Apr;123(4 Suppl):S39-46
Date: 2010-05-04   Read: 154164

Am J Med. 2010 Apr;123(4 Suppl):S39-46

Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia

Restrepo MI, Frei CR

Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.



Next Heterogeneous vancomycin resistance in S. aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother. 2010;44:844-50 2010-05-27 157828
Previous CA-MRSA immune evasion and virulence. J Mol Med. 2010 Feb;88(2):109-14 2010-04-01 156859
޴ٷΰ ΰ